

Hector Tamez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10565900/hector-tamez-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

4,310
citations

22
h-index

47
g-index

47
ext. papers

4,862
ext. citations

10.2
avg, IF

4.71
L-index

#	Paper	IF	Citations
46	Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , 2008 , 359, 584-92	59.2	1320
45	Vitamin D-binding protein and vitamin D status of black Americans and white Americans. <i>New England Journal of Medicine</i> , 2013 , 369, 1991-2000	59.2	758
44	Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 674-84	27.4	406
43	Phosphorus binders and survival on hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 388-96	12.7	299
42	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 16810-5	11.5	274
41	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 903-13	12.7	164
40	Impact of activated vitamin D and race on survival among hemodialysis patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1379-88	12.7	145
39	Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. <i>Clinical Infectious Diseases</i> , 2009 , 48, 418-24	11.6	115
38	Active vitamin D treatment for reduction of residual proteinuria: a systematic review. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 1863-71	12.7	113
37	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. <i>American Heart Journal</i> , 2012 , 164, 902-9.e2	4.9	95
36	Plasma gelsolin and circulating actin correlate with hemodialysis mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1140-8	12.7	71
35	Nutritional vitamin D supplementation in dialysis: a randomized trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 611-9	6.9	52
34	Klotho variants and chronic hemodialysis mortality. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1847-55	6.5	45
33	Does vitamin D modulate blood pressure?. <i>Current Opinion in Nephrology and Hypertension</i> , 2013 , 22, 204-9	3.5	44
32	Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). <i>BoneKEy Reports</i> , 2014 , 3, 498		42
31	Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. <i>Kidney International</i> , 2013 , 83, 1130-5	9.9	40
30	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. <i>International Journal of Nephrology</i> , 2015 , 2015, 108139	1.7	38

29	Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. <i>PLoS ONE</i> , 2010 , 5, e9246	3.7	37
28	Vitamin D and hypertension: an update and review. <i>Current Opinion in Nephrology and Hypertension</i> , 2012 , 21, 492-9	3.5	32
27	Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients: clinical implications. <i>American Journal of Nephrology</i> , 2012 , 36, 451-8	4.6	28
26	Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 1927-34	6.9	27
25	Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative. <i>JAMA Cardiology</i> , 2019 , 4, 100-109	16.2	27
24	Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. <i>American Journal of Nephrology</i> , 2013 , 38, 12-8	4.6	20
23	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry. <i>JAMA Cardiology</i> , 2019 , 4, 110-118	16.2	15
22	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. <i>American Heart Journal</i> , 2019 , 212, 64-71	4.9	14
21	Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 517-526	5	12
20	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement: Findings From the EXTEND Study. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008231	6	12
19	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 651-658	5	11
18	Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 849-856	2.7	11
17	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. <i>Circulation</i> , 2020 , 142, 203-213	16.7	8
16	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006589	5.8	6
15	Impact of new vitamin D data on future studies and treatment. <i>Current Opinion in Nephrology and Hypertension</i> , 2013 , 22, 377-82	3.5	5
14	The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). <i>Angiology</i> , 2020 , 71, 274-280	2.1	5
13	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 673-677	16.2	4
12	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2021 ,	16.7	4

11	Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. <i>EuroIntervention</i> , 2021 , 17, e380-e387	3.1	4
10	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2020 , 142, 306-308	16.7	3
9	Serum phospholipid fraction of polyunsaturated fatty acids is the preferred indicator for nutrition and health status in hemodialysis patients. <i>Journal of Nutritional Biochemistry</i> , 2016 , 38, 18-24	6.3	1
8	Reply to "The role of fibroblast growth factor-23 in left atrial volume". <i>American Heart Journal</i> , 2013 , 165, e23	4.9	1
7	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN-CTO Registry.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024056	6	1
6	African Americans with left ventricular hypertrophy and chronic kidney disease: what should we do?. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1969-1970	4.3	
5	Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009 , 49, 164-165	11.6	
4	Vitamin D and Its Effects on the Heart 2015 , 107-116		
3	Role of Vitamin D and Vitamin D Analogs for Bone Health and Survival in Chronic Kidney Disease 2010 , 955-965		
2	Phospholipid PUFA: a better indicator for assessing health risks. <i>FASEB Journal</i> , 2013 , 27, 1072.16	0.9	
1	Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 74, 1023-1031	0.7	